| Bile Duct Neoplasm altered in cohorts of …ALTERED_INderived139 of 139show fewer |
|---|
| ← altered in cohorts of | HTR6 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHDC7A 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MRTO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TAS1R2 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMCO4 42 / 51 cases (82 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AADACL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ACTL8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AHDC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AKR7A3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALDH4A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALPL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARHGEF10L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP13A2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C1orf158 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMK2N1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAMTA1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAPZB 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CLCN6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DDOST 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DHRS3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAJC11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | E2F2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ECE1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EIF4G3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ELOA 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EMC1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM43B 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXO42 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HMGCL 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPCL4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPR 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HP1BP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HSPG2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR1D 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IFFO2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | IGSF21 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KDM1A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KIF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LACTBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LDLRAD2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC38 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LUZP1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MFAP2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MICOS10-NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MST1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MUL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBL1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBPF1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NBPF3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NPHP4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OTUD3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PADI6 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PAX7 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDIK1L 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PDPN 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PINK1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PITHD1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2A 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2C 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2E 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLA2G2F 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLEKHG5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF12 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF14 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF17 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF18 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF20 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF25 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF26 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF27 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF33 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF8 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRAMEF9 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RAP1GAP 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RCC2 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF186 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL11 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RPL22 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SH2D5 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC66A1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPEN 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TEX46 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THAP3 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBR4 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBXN10 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP48 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS13D 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VWA5B1 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF436 41 / 51 cases (80 %) · ssm · TCGA-CHOL | — | — | Cholangiocarcinoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TP53 147 / 417 cases (35 %) · ssm · chol_icgc_2017 · largest of 5 cohorts | — | — | Cholangiocarcinoma | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | IDH1 85 / 412 cases (21 %) · ssm · ihch_msk_2021 · largest of 3 cohorts | — | — | Intrahepatic Cholangiocarcinoma | 3 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ARID1A 80 / 417 cases (19 %) · ssm · chol_icgc_2017 · largest of 5 cohorts | — | — | Cholangiocarcinoma | 5 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KRAS 76 / 417 cases (18 %) · ssm · chol_icgc_2017 · largest of 3 cohorts | — | — | Cholangiocarcinoma | 3 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SMAD4 60 / 417 cases (14 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SYNE1 46 / 417 cases (11 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC16 44 / 417 cases (11 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BAP1 39 / 417 cases (9.4 %) · ssm · chol_icgc_2017 · largest of 4 cohorts | — | — | Cholangiocarcinoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LRP1B 39 / 417 cases (9.4 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FSIP2 37 / 417 cases (8.9 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | EPHA2 36 / 417 cases (8.6 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PCLO 36 / 417 cases (8.6 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CSMD3 34 / 417 cases (8.2 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SACS 34 / 417 cases (8.2 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | APC 33 / 417 cases (7.9 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RYR2 32 / 417 cases (7.7 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | OBSCN 31 / 417 cases (7.4 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | HMCN1 30 / 417 cases (7.2 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KMT2D 30 / 417 cases (7.2 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ELF3 29 / 417 cases (7.0 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | KMT2C 29 / 417 cases (7.0 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PBRM1 29 / 417 cases (7.0 %) · ssm · chol_icgc_2017 · largest of 4 cohorts | — | — | Cholangiocarcinoma | 4 | Observed | cbioportal | graph → |
| ← altered in cohorts of | LRP2 28 / 417 cases (6.7 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | MUC6 28 / 417 cases (6.7 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | FAT3 27 / 417 cases (6.5 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | BRAF 26 / 412 cases (6.3 %) · ssm · ihch_msk_2021 | — | — | Intrahepatic Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ARID2 25 / 417 cases (6.0 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ADGRV1 24 / 417 cases (5.8 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CSMD1 24 / 417 cases (5.8 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | NEB 24 / 417 cases (5.8 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PLEC 24 / 417 cases (5.8 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SPTA1 24 / 417 cases (5.8 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ATM 23 / 417 cases (5.5 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PXDN 23 / 417 cases (5.5 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | STK11 23 / 417 cases (5.5 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ADAMTS20 22 / 417 cases (5.3 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RNF43 22 / 417 cases (5.3 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | GNAS 21 / 417 cases (5.0 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | PIK3CA 21 / 417 cases (5.0 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | RNF213 21 / 417 cases (5.0 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | SF3B1 21 / 417 cases (5.0 %) · ssm · chol_icgc_2017 | — | — | Cholangiocarcinoma | 1 | Observed | cbioportal | graph → |